What did we learn, what are we going to do? Wrap-up

Friday, 16. September 2011 | 11:15 Uhr


Gerd Folkers


Collegium Helveticum


All structural and organizational spheres have to be considered in personalized medicine. Genotypes only indicate the potential of a disease. But all the other factors need to be taken into account as well. The traditional approach to medicine often starts on a molecular level. In contrast to this, there is the opinion of the patient who does not always agree with medicine. The speakers gave many examples of useful applications of personalized medicine.

Professor Gerd Folkers, Collegium Helveticum, questioned the principles of truth standards and no harm outlined by Dr. Vayena. With the introduction of new concepts, big challenges in the field of cultural differences and doctor-patient relationships have to be faced. What has to be done? There is the gigantic task of converging data bases and methods in order to have one reliable method at the end. Constant discussion on this issue is necessary. For this purpose, stakeholders have to be indentified and integrated.

Gerd Folkers

He has been Full Professor of Pharmaceutical Chemistry at ETH Zurich since 1994 and Associate Professor since 1991. He took the Chair of the Collegium Helveticum on the first of October 2004.

Born in Andernach/Rhein (Germany) in 1953, Folkers studied Pharmacy at the University of Bonn where he earned his doctorate subsequently. With his doctoral advisor he relocated to the University of Tübingen in 1983 and completed his habilitation there in 1989. During a stay with H.-D. Höltje in Berne in 1984/85, he studied new research methods in computer-aided molecular design. He expanded his knowledge during other stays abroad, especially at the Birkbeck College in London and at the Texas A&M University in College Station.

His research focus lies on the molecular interaction between drugs and its binding sites in vivo. Folkers is particularly interested in the strong integration of computer-aided modelling and relevant biochemical/biophysical experiments. Besides the research on molecular mechanism of «conventional» nucleoside therapeutics against virus infection and cancer, his special interest has shifted to immuno therapeutics.

He is editor of the journals «QSAR» and «Pharmaceutica Acta Helvetiae», author and editor of diverse scientific books, Vice President of the «Schweizerische Gesellschaft der Pharmazeutischen Wissenschaften», member of the executive board of the «Schweizerische Akademie der Technischen Wissenschaften» as well as a member of the board of many international scientific societies.

Donators and Partners

The ETH Board is responsible for the strategic leadership of the ETH domain and assumes the supervision of its institutions. Its close relationship with the ETH Council has contributed to the successful continuation of Academia Engelberg Foundation since 2000.

The Foundation promotes research into the connecting human fundamentals of science. Academia Engelberg Foundation and the Foundation for Basic Research in Human Sciences have entered into a cooperation agreement for the period 2011 to 2015.

Helvetia is a quality-oriented comprehensive insurance company with over 150 years of experience. Academia Engelberg Foundation is convinced it will be able to use important synergies from the partnership starting in 2015.

A partnership with the University of Lucerne has existed since summer 2013. Since 2016 we have also a parthership with the Faculty of Economics and Management of the University of Lucerne. Through these partnerships, synergies are used and joint projects are tested and realized. The University of Lucerne currently consists of three faculties: the faculties for Theology, Culture and Social Sciences, and Law.